Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. is the subject of a Schedule 13G reporting that Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh collectively report beneficial ownership of 3,298,236 shares of common stock. This represents 7.06% of the common stock, calculated using 46,705,410 shares outstanding as of May 8, 2026, as reported by the company.

Dr. Aghazadeh, as portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures, is listed as a Reporting Person, with sole voting and dispositive power over these shares. The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P., and the Reporting Persons state that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.

Key Figures

Beneficial ownership: 3,298,236 shares Percent of class owned: 7.06% Shares outstanding baseline: 46,705,410 shares +4 more

7 metrics

Beneficial ownership 3,298,236 shares Shares of Hemab Therapeutics common stock reported as beneficially owned by Behzad Aghazadeh

Percent of class owned 7.06% Portion of Hemab Therapeutics common stock class reported as beneficially owned

Shares outstanding baseline 46,705,410 shares Common shares outstanding as of May 8, 2026 used to calculate ownership percentage

Avoro Capital Advisors position 1,925,150 shares Shares with sole voting and dispositive power reported by Avoro Capital Advisors

Avoro Ventures position 1,373,086 shares Shares with sole voting and dispositive power reported by Avoro Ventures

Avoro Capital Advisors percent 4.12% Percent of Hemab Therapeutics common stock class attributed to Avoro Capital Advisors

Avoro Ventures percent 2.94% Percent of Hemab Therapeutics common stock class attributed to Avoro Ventures

Key Terms

beneficial owner, sole voting power, sole dispositive power, investment advisory and management services, +1 more

5 terms

beneficial owner regulatory

"not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power regulatory

"5 | Sole Voting Power 1,925,150.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power regulatory

"7 | Sole Dispositive Power 1,925,150.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

investment advisory and management services financial

"provides investment advisory and management services and has acquired the shares of Common Stock"

Schedule 13G regulatory

"This statement is filed by: (i) Avoro Capital Advisors LLC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What stake in COAG does Avoro and Behzad Aghazadeh report in this Schedule 13G?

They report beneficial ownership of 3,298,236 shares of Hemab Therapeutics common stock, representing 7.06% of the outstanding shares based on 46,705,410 shares outstanding as of May 8, 2026.

How many COAG shares does each Avoro entity report owning?

Avoro Capital Advisors reports 1,925,150 shares with sole voting and dispositive power, while Avoro Ventures reports 1,373,086 shares with sole voting and dispositive power, all held for investment on behalf of their respective funds.

How was the 7.06% ownership in COAG calculated for this filing?

The 7.06% ownership figure is based on an aggregate of 46,705,410 Hemab Therapeutics common shares outstanding as of May 8, 2026, as reported in the company’s Form 10-Q for the quarter ended March 31, 2026.

For what purpose were the COAG shares acquired by Avoro and related funds?

The shares of Hemab Therapeutics common stock were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P., according to the Reporting Persons’ disclosure.

Do the Reporting Persons share voting or dispositive power over COAG shares?

The filing indicates sole voting and sole dispositive power over the reported shares for each Reporting Person and shows no shared voting or dispositive power in the cover-page data.

Who are the Reporting Persons in this COAG Schedule 13G and where are they based?

The Reporting Persons are Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh. Their business address is 110 Greene Street, Suite 800, New York, NY 10012; Dr. Aghazadeh is a U.S. citizen.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 09:02 AM Accepted by SEC EDGAR 08/14/2026 - 09:01 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hemab Therapeutics Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

423494103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Avoro Capital Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,925,150.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,925,150.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,925,150.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.12 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Avoro Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,373,086.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,373,086.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,373,086.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.94 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Behzad Aghazadeh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,298,236.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,298,236.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,298,236.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.06 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hemab Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 101 Main Street, Suite 1220, Cambridge, Massachusetts 02142
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), which provides investment advisory and management services and has acquired the shares of common stock, par value $0.001 per share ("Common Stock"), of Hemab Therapeutics Holdings, Inc., a Delaware corporation (the "Company"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, (ii) Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures"), which provides investment advisory and management services and has acquired the shares of Common Stock solely for investment purposes on behalf of Avoro Ventures Fund L.P., a Delaware limited partnership, and (iii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro Capital Advisors, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.
(c)	Citizenship: Avoro Capital Advisors is a Delaware limited liability company. Avoro Ventures is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 423494103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 46,705,410 shares of Common Stock outstanding as of May 8, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 21, 2026.
(b)	Percent of class: 7.06%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Avoro Capital Advisors LLC

Signature:	/s/ Scott Epstein
Name/Title:	Scott Epstein, Chief Operating Officer and Chief Compliance Officer
Date:	08/14/2026

Avoro Ventures LLC

Signature:	/s/ Scott Epstein
Name/Title:	Scott Epstein, Chief Operating Officer and Chief Compliance Officer
Date:	08/14/2026

Behzad Aghazadeh

Signature:	/s/ Behzad Aghazadeh
Name/Title:	Behzad Aghazadeh, Individually
Date:	08/14/2026

Exhibit Information

Exhibit 99.1: Joint Filing Agreement